Atrial fibrillation
Conditions
Interventions
Experimental group:DOACs
Control group:Warfarin
Sponsors
The Second Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
50 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged = 50 years, and <75 years at the time of inclusion; 2. Valvular heart disease with paroxysmal or persistent atrial fibrillation or atrial flutter more than 48 hours after biological valve replacement; 3. Sign informed consent;
Exclusion criteria
Exclusion criteria: 1. Presence of cardiovascular-related diseases, such as definite cardiac thrombosis, malignant tumor, active infective endocarditis or uncontrolled hypertension (>160/100mmHg); 2. Active internal bleeding or high risk of bleeding, such as major non-cardiac surgery or trauma in the past 30 days; 3. History of embolism with high bleeding risk, such as disabling stroke in the past 3 months, thromboembolic event, arteriovenous thrombosis or acute myocardial infarction event occurred 2 weeks before randomization; 4. Long-term use of aspirin >= 100 mg/day or bispecific antibody therapy, non-steroidal anti-inflammatory drugs or oral hormones is required for chronic medication; 5. Anemia HB 3 times the upper limit of normal, creatinine clearance rate <30 ml/min); 7. Those who participate in any kind of clinical trial of a drug that has not been officially approved for marketing by the state; 8. The investigator judged that the follow-up could not be completed;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite endpoints of Major cardiovascular events, haemorrhage events or deaths; | — |
Secondary
| Measure | Time frame |
|---|---|
| Composite end points of cardiac death or embolic events;Bleeding events; | — |
Countries
China
Contacts
Public ContactHuihui Bao
The Second Affiliated Hospital of Nanchang University
Outcome results
None listed